Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
PBS Top Five
Infectious diseases - a market in suspension
The infectious diseases market is expected to surge once new hep C treatments such as Sovaldi and Harvoni are PBS listed but right now it looks like prescribers are holding back.
Pipeline Monitor
Fast track for pancreatic cancer treatment
The FDA fast tracks filings for pancreatic cancer, multiple myeloma plus new filings on horizon for asthma and eye disease.
Working Life
Overseas posts not just for managers
You don't have to be at managerial level to gain an overseas posting from some of Australia's top pharma companies. How's it done?
Approvals Action
New generic a threat to Mercury Pharma
A first time generic approval for PBS listed antidepressant Parnate threatens tough competition for Mercury Pharma Australia.
Special Report
Mergers change shape of Aussie pharma
The almost US$212 billion dollars worth of M&A in pharma last year is already changing the local industry landscape and there is almost certainly more to come.